Acemoglu, D., & Linn, J. (2004). Market size in innovation: Theory and evidence from the pharmaceutical industry. Quarterly Journal of Economics, 3, 1049–1090.
Averch, H., & Johnson, L. L. (1962). Behavior of the firm under regulatory constraint. American Economic Review, 52(5), 1052–1069.
Berndt, E. R., & Trusheim, M. R. (2015). Biosimilar and biobetter scenarios for the US and Europe: What should we expect? In A. Rosenberg & B. Demeule (Eds.), Biobetters: Protein engineering to approach the curative (pp. 315–360). New York, NY: Springer.
Berry, S. T. (1992). Estimation of a model of entry in the airline industry. Econometrica, 60, 889–917.
Bresnahan, T. F., & Reiss, P. C. (1991). Entry and competition in concentrated markets. Journal of Political Economy, 99(5), 977–1009.
Bulow, J. (2004). The gaming of pharmaceutical patents. Innovation Policy and the Economy, 4, 145–187.
Cutroneo, P. M., Isgrò, V., Russo, A., Ientile, V., Sottosanti, L., Pimpinella, G., et al. (2014). Safety profile of biological medicines as compared with non-biologicals: An analysis of initial spontaneous reporting system database. Drug Safety, 37, 961–970.
Danzon, P. M., & Chao, L.-W. (2000). Does regulation drive out competition in pharmaceutical markets? Journal of Law and Economics, 43(2), 311–358.
DiMasi, J. A., & Grabowski, H. G. (2007). The cost of biopharmaceutical R&D: Is biotech different? Managerial and Decision Economics, 28(4–5), 469–479.
Dubois, P., de Mouzon, O., Scott Morton, F. M., & Seabright, P. (2015). Market size and pharmaceutical innovation. RAND Journal of Economics, 46(4), 844–871.
Duggan, M., & Scott Morton, F. M. (2010). The effect of Medicare Part D on pharmaceutical prices and utilization. American Economic Review, 100(1), 590–607.
FDA. (2017). Considerations in demonstrating interchangeability with a reference product; Draft Guidance”. Food and Drug Administration.
Ganslandt, M., & Maskus, K. E. (2004). Parallel imports and the pricing of pharmaceutical products: Evidence from the European Union. Journal of Health Economics, 23(5), 1035–1057.
Generics and Biosimilars Initiative (GABI). (2015). No relevant difference in ADRs from biosimilars and originators. http://gabionline.net/Biosimilars/Research/No-relevant-difference-in-ADRs-from-biosimilars-and-originators. Accessed 26 February 2018.
Grabowski, H. (2008). Follow-on biologics: Data exclusivity and the balance between innovation and competition. Nature Reviews Drug Discovery, 7(6), 479–488.
Grabowski, H., Cockburn, I., & Long, G. (2006). The market for follow-on biologics: How will it evolve? Health Affairs, 25(5), 1291–1301.
Grabowski, H. G., Ridley, D. B., & Schulman, K. A. (2007). Entry and competition in generic biologics. Managerial and Decision Economics, 28(4–5), 439–451.
Grabowski, H., & Vernon, J. (1986). Longer patents for lower imitation barriers: The 1984 Drug Act. American Economic Review, 76(2), 195–198.
Hamburg, M. A. (2014). Celebrating 30 years of easier access to cost-saving generic drugs. FDA Voice. http://blogs.fda.gov/fdavoice/index.php/2014/09/celebrating-30-years-of-easier-access-to-cost-saving-generic-drugs. Accessed 26 February 2018.
Inderst, R., & Valletti, T. (2009). Price discrimination in input markets. RAND Journal of Economics, 40(1), 1–19.
Kozlowski, S., Woodcock, J., Midthun, K., & Sherman, R. B. (2011). Developing the nation’s biosimilars program. New England Journal of Medicine, 365(5), 385–388.
Kyle, M. K. (2007). Pharmaceutical price controls and entry strategies. Review of Economics and Statistics, 89(1), 88–99.
Laffont, J.-J., & Tirole, J. (1993). A theory of incentives in procurement and regulation. Boston: MIT Press.
MacNeil, J. S., & Douglas, F. (2007). Challenges to establishing a regulatory framework for approving follow-on biologics: A background paper. MIT Center for Biological Innovation. http://cbi.mit.edu/wp-content/uploads/2011/04/FOB_macneil.pdf. Accessed 26 February 2018.
Reiffen, D., & Ward, M. R. (2005). Generic drug industry dynamics. Review of Economics and Statistics, 87(1), 37–49.
Rovira, J., Espin, J., Garcia, L., & Olry de Labry, A. (2011). The impact of biosimilars’ entry in the EU Market. Granada: Andalusian School of Public Health.
Sarpatwari, A., Avorn, J., & Kesselheim, A. S. (2015). Progress and hurdles for follow-on biologics. New England Journal of Medicine, 372(25), 2380–2382.
Scott Morton, F. M. (1999). Entry decisions in the generic pharmaceutical industry. The RAND Journal of Economics, 30(3), 421–440.
Scott Morton, F. M. (2000). Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization, 18(7), 1085–1104.
Vermeer, N. (2012). Traceability of biopharmaceuticals in spontaneous reporting systems. European Medicines Agency, presentation. http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2012/05/WC500127934.pdf. Accessed 26 February 2018.
Vermeer, N. S., Straus, S. M., Mantel-Teeuwisse, A. K., Domergue, F., Egberts, T. C., Leufkens, H. G., et al. (2013). Traceability of biopharmaceuticals in spontaneous reporting systems: A cross-sectional study in the FDA adverse event reporting system (FAERS) and EudraVigilance databases. Drug Safety, 36, 617–625.